Bionano Genomics（BNGO）株式概要
バイオナノ・ゲノミクス社は、その子会社とともに、南北アメリカ、ヨーロッパ、中東、アフリカ、中国、日本、韓国、シンガポール、インド、オーストラリアでゲノム解析ソリューションを提供している。 詳細
BNGO Community Fair Values
Create NarrativeSee what 34 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Bionano Genomics, Inc. 競合他社
価格と性能
| 過去の株価 | |
|---|---|
| 現在の株価 | US$1.22 |
| 52週高値 | US$5.50 |
| 52週安値 | US$1.06 |
| ベータ | 1.62 |
| 1ヶ月の変化 | 0.83% |
| 3ヶ月変化 | 6.09% |
| 1年変化 | -67.64% |
| 3年間の変化 | -99.71% |
| 5年間の変化 | -99.90% |
| IPOからの変化 | -99.90% |
最新ニュース
ナラティブの更新 • May 25
BNGO: Growing Clinical Use Cases Will Support Future Upside Potential
Analysts have nudged their price target on Bionano Genomics slightly higher to $6.00, citing updated assumptions for discount rate, revenue growth, profit margin and future P/E, which modestly adjust their outlook on the stock. What's in the News The company issued revenue guidance for Q2 2026, targeting US$7.5 million to US$7.8 million in revenue.ナラティブの更新 • May 03
BNGO: Clinical Evidence For Genome Mapping Will Support Long-Term Upside
Analysts have maintained their $6.00 price target for Bionano Genomics, noting only minor adjustments to assumptions for discount rate, revenue growth, profit margin and future P/E that do not materially change their overall view on the stock. What's in the News Bionano Genomics reported that its auditor, BDO LLP, issued an unqualified opinion in the 2025 Form 10-K while expressing doubt about the company’s ability to continue as a going concern, highlighting funding and liquidity risk that equity holders should monitor closely (10-K filing).ナラティブの更新 • Apr 19
BNGO: Gene Editing QC And Hematology Evidence Will Drive Long-Term Upside
Analysts have reduced their price targets for Bionano Genomics, lowering updated fair value estimates to $6.00 from $8.00, alongside slightly lower revenue growth and profit margin assumptions and a marginally reduced future P/E outlook. What's in the News Bionano Genomics published a multicenter study in the American Journal of Hematology showing that optical genome mapping, or OGM, identified pathogenic or likely pathogenic abnormalities in multiple myeloma samples, including cases where traditional methods such as karyotyping, FISH, and NGS had limited success or returned no result (American Journal of Hematology).Recent updates
ナラティブの更新 • May 25
BNGO: Growing Clinical Use Cases Will Support Future Upside Potential
Analysts have nudged their price target on Bionano Genomics slightly higher to $6.00, citing updated assumptions for discount rate, revenue growth, profit margin and future P/E, which modestly adjust their outlook on the stock. What's in the News The company issued revenue guidance for Q2 2026, targeting US$7.5 million to US$7.8 million in revenue.ナラティブの更新 • May 03
BNGO: Clinical Evidence For Genome Mapping Will Support Long-Term Upside
Analysts have maintained their $6.00 price target for Bionano Genomics, noting only minor adjustments to assumptions for discount rate, revenue growth, profit margin and future P/E that do not materially change their overall view on the stock. What's in the News Bionano Genomics reported that its auditor, BDO LLP, issued an unqualified opinion in the 2025 Form 10-K while expressing doubt about the company’s ability to continue as a going concern, highlighting funding and liquidity risk that equity holders should monitor closely (10-K filing).ナラティブの更新 • Apr 19
BNGO: Gene Editing QC And Hematology Evidence Will Drive Long-Term Upside
Analysts have reduced their price targets for Bionano Genomics, lowering updated fair value estimates to $6.00 from $8.00, alongside slightly lower revenue growth and profit margin assumptions and a marginally reduced future P/E outlook. What's in the News Bionano Genomics published a multicenter study in the American Journal of Hematology showing that optical genome mapping, or OGM, identified pathogenic or likely pathogenic abnormalities in multiple myeloma samples, including cases where traditional methods such as karyotyping, FISH, and NGS had limited success or returned no result (American Journal of Hematology).
ナラティブの更新 • Apr 05
BNGO: Future Gene Editing Quality Control Breakthroughs Will Drive Upside Potential
Analysts have cut their price target on Bionano Genomics roughly in half, to around $4.00 from about $8.00, pointing to a higher discount rate, slightly softer revenue growth expectations near 26%, a modestly better profit margin near 16%, and a higher future P/E multiple closer to 8x as key drivers of the reset. What's in the News A multicenter study in the American Journal of Hematology reported that Bionano's optical genome mapping, or OGM, was concordant with traditional methods in multiple myeloma and identified pathogenic or likely pathogenic abnormalities in a large cohort of 211 samples, including cases where standard tests such as karyotyping and FISH did not yield results (American Journal of Hematology).
ナラティブの更新 • Mar 22
BNGO: Gene Editing Safety Data Will Support Future Upside Potential
Analysts have adjusted their price target for Bionano Genomics slightly, reflecting updated assumptions around discount rate, profit margin, revenue growth and future P/E. Together, these factors point to a modest recalibration of their valuation outlook in dollar terms.ナラティブの更新 • Mar 07
BNGO: Gene Editing Safety Insights Will Support Long-Term Upside Potential
Analysts have lowered their price target on Bionano Genomics by $2.00 to $5.50, citing updated assumptions for fair value, discount rate, revenue growth, profit margin, and future P/E. These changes collectively point to a more conservative outlook for the shares.ナラティブの更新 • Feb 20
BNGO: Gene Editing Study And Mapping Sensitivity Will Support Future Upside
Analysts have raised their price target for Bionano Genomics to $12.59 from $12.37, citing updated assumptions for the discount rate, revenue growth, profit margin, and future P/E that reflect a recalibrated risk and earnings profile. What's in the News Bionano Genomics highlighted a peer-reviewed study in Molecular Therapy: Methods & Clinical Development that used optical genome mapping, or OGM, to assess genomic alterations from multiple gene editing approaches, including transposons, lentiviral transduction, and CRISPR-Cas9 locus insertion (Key Developments).ナラティブの更新 • Feb 06
BNGO: Gene Editing QC Study Will Support Long-Term Upside
Analysts have trimmed their price targets for Bionano Genomics, citing slightly higher assumed discount rates and modest tweaks to long term revenue growth, profit margin and future P/E assumptions that leave their fair value estimate broadly unchanged at around $8.00. What's in the News Bionano Genomics highlighted a peer-reviewed study in Molecular Therapy: Methods & Clinical Development that used its optical genome mapping (OGM) technology to detect genomic alterations introduced by transposons, lentiviral transduction and CRISPR-Cas9 locus insertion in human iPSC lines, supporting OGM as a potential tool for genome integrity QC in gene editing workflows (Key Developments).分析記事 • Jan 30
Market Cool On Bionano Genomics, Inc.'s (NASDAQ:BNGO) Revenues
With a price-to-sales (or "P/S") ratio of 0.5x Bionano Genomics, Inc. ( NASDAQ:BNGO ) may be sending very bullish...ナラティブの更新 • Jan 23
BNGO: Clinical Study And Genome Mapping Progress Will Support Future Upside
Analysts have adjusted their price target on Bionano Genomics slightly, reflecting modest tweaks to assumptions on discount rate, profit margin, and future P/E. These changes keep their fair value estimate broadly unchanged at about $7.50 per share.ナラティブの更新 • Jan 09
BNGO: Leukemia Study And 2025 Revenue Outlook Will Support Long-Term Upside
Analysts have slightly adjusted their price target for Bionano Genomics, citing modest tweaks in assumptions around discount rate, revenue growth, profit margin, and future P/E as the drivers of this update. What's in the News Bionano Genomics issued earnings guidance for the fourth quarter of 2025, with revenue projected in a range of US$7.5 million to US$7.9 million.ナラティブの更新 • Dec 23
BNGO: Study-Driven Revenue Outlook Will Support Stronger Long-Term Upside Potential
Analysts have lowered their fair value estimate for Bionano Genomics from 11.00 dollars to 8.00 dollars. This reflects a higher perceived risk and cost of capital, despite slightly stronger expectations for revenue growth, profitability, and future valuation multiples.ナラティブの更新 • Dec 09
BNGO: Clinical Study Momentum Will Drive Stronger Demand And Upside Through 2025
Analysts have modestly reiterated their outlook on Bionano Genomics, keeping the price target effectively unchanged as incremental tweaks to the discount rate, revenue growth, and margin assumptions suggest a steady, but not markedly altered, risk reward profile. What's in the News Bionano Genomics issued new revenue guidance for fourth quarter 2025, targeting $7.5 million to $7.9 million, while reiterating full year 2025 revenue expectations of $26.0 million to $30.0 million (company guidance filing).ナラティブの更新 • Nov 25
BNGO: Clinical Study Results Will Drive Increased Demand Through 2025
Analysts have lowered their price target for Bionano Genomics from $9.50 to $7.50 per share, citing updated forecasts for valuation and growth. What's in the News Bionano Genomics initiated earnings guidance for the fourth quarter of 2025, projecting revenue between $7.5 million and $7.9 million, and reiterated full-year 2025 revenue guidance of $26.0 million to $30.0 million (company guidance).分析記事 • Sep 14
A Piece Of The Puzzle Missing From Bionano Genomics, Inc.'s (NASDAQ:BNGO) 28% Share Price Climb
Bionano Genomics, Inc. ( NASDAQ:BNGO ) shareholders would be excited to see that the share price has had a great month...ナラティブの更新 • Aug 15
VIA Software And Optical Genome Mapping Will Improve Laboratory Efficiency
With both the consensus price target and future P/E holding steady, no notable valuation shift is apparent for Bionano Genomics, keeping fair value unchanged at $9.00. What's in the News Peer-reviewed study demonstrated Bionano's optical genome mapping (OGM) detects novel oncogenic structural variants in infant/toddler T-cell acute lymphoblastic leukemia missed by conventional cytogenetics, identifying distinct prognostic subgroups.分析記事 • Jul 30
Investors Continue Waiting On Sidelines For Bionano Genomics, Inc. (NASDAQ:BNGO)
Bionano Genomics, Inc.'s ( NASDAQ:BNGO ) price-to-sales (or "P/S") ratio of 0.4x might make it look like a strong buy...
新しいナラティブ • Apr 16
VIA Software And Optical Genome Mapping Will Improve Laboratory Efficiency
Enhancements in customer utilization and lab efficiency are projected to boost consumable sales and revenue growth.分析記事 • Apr 05
Revenues Working Against Bionano Genomics, Inc.'s (NASDAQ:BNGO) Share Price Following 26% Dive
To the annoyance of some shareholders, Bionano Genomics, Inc. ( NASDAQ:BNGO ) shares are down a considerable 26% in the...分析記事 • Feb 11
Slammed 62% Bionano Genomics, Inc. (NASDAQ:BNGO) Screens Well Here But There Might Be A Catch
Bionano Genomics, Inc. ( NASDAQ:BNGO ) shareholders that were waiting for something to happen have been dealt a blow...分析記事 • Dec 17
Bionano Genomics, Inc. (NASDAQ:BNGO) Might Not Be As Mispriced As It Looks
Bionano Genomics, Inc.'s ( NASDAQ:BNGO ) price-to-sales (or "P/S") ratio of 0.7x might make it look like a strong buy...分析記事 • Aug 29
Many Still Looking Away From Bionano Genomics, Inc. (NASDAQ:BNGO)
Bionano Genomics, Inc.'s ( NASDAQ:BNGO ) price-to-sales (or "P/S") ratio of 1.1x might make it look like a strong buy...株主還元
| BNGO | US Life Sciences | US 市場 | |
|---|---|---|---|
| 7D | 4.3% | 2.0% | 2.5% |
| 1Y | -67.6% | 5.3% | 26.4% |
業界別リターン: BNGO過去 1 年間で5.3 % の収益を上げたUS Life Sciences業界を下回りました。
リターン対市場: BNGOは、過去 1 年間で26.4 % のリターンを上げたUS市場を下回りました。
価格変動
| BNGO volatility | |
|---|---|
| BNGO Average Weekly Movement | 11.0% |
| Life Sciences Industry Average Movement | 8.1% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.5% |
| 10% least volatile stocks in US Market | 3.1% |
安定した株価: BNGO 、 US市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。
時間の経過による変動: BNGOの 週次ボラティリティ ( 11% ) は過去 1 年間安定しています。
会社概要
| 設立 | 従業員 | CEO（最高経営責任者 | ウェブサイト |
|---|---|---|---|
| 2003 | 96 | Al Luderer | bionano.com |
バイオナノ・ゲノミクス社は、その子会社とともに、南北アメリカ、ヨーロッパ、中東、アフリカ、中国、日本、韓国、シンガポール、インド、オーストラリアでゲノム解析ソリューションを提供しています。同社はゲノム解析ソフトウエアを提供しており、ゲノミクスラボが様々なプラットフォームでデータを解析・解釈し、情報量の多いデータの可視化を行うことで、原因バリアントの合理的でシンプルな報告を可能にしている。また、ゲノム解析や遺伝子の変異と機能の理解のための光ゲノムマッピングによる構造変異解析のためのサンプルから結果までのソリューションであるSaphyrシステムとStratysシステム、1分子イメージャーであるSaphyr装置とStratys装置も提供している；DNA直鎖化用ナノチャンネルアレイをパッケージングした消耗品であるSaphyr Chip、超高分子量DNAの抽出と標識のための試薬とプロトコルを提供するBionano Prep KitsとDNA標識キット、核酸分子を分離・精製するIonic purification system。さらに、同社はSaphyr、Stratys、Bionanoコンピュートサーバー、細胞遺伝学と分子遺伝学のソリューションのための1つのソリューションを提供するVIAソフトウェアを提供している。さらに、FirstStepDx PLUS、自閉症スペクトラム障害、発達遅延、知的障害を持つ人の根本的な遺伝的原因を特定するための染色体マイクロアレイ、脆弱X症候群（FXS）検査サービスなどの検査・ラボサービスを提供している；NextStepDx PLUS：小児発達障害に関連する遺伝子変異を特定するエクソームシークエンシング検査、OGM-Dx HemeOne検査、OGM-Dx FSHD：FSHD1型が疑われる人のための検査、包括的検査のためのOGM-Dx Postnatal Whole Genome SVおよびOGM-Dx Prenatal Whole Genome SV。バイオナノ・ジェノミクス社は2003年に設立され、カリフォルニア州サンディエゴに本社を置いています。
Bionano Genomics, Inc. 基礎のまとめ
| BNGO 基礎統計学 | |
|---|---|
| 時価総額 | US$13.75m |
| 収益（TTM） | -US$31.60m |
| 売上高(TTM) | US$28.74m |
0.5x
P/Sレシオ-0.4x
PER（株価収益率BNGO は割高か？
公正価値と評価分析を参照収益と収入
| BNGO 損益計算書（TTM） | |
|---|---|
| 収益 | US$28.74m |
| 売上原価 | US$15.24m |
| 売上総利益 | US$13.50m |
| その他の費用 | US$45.10m |
| 収益 | -US$31.60m |
直近の収益報告
Mar 31, 2026
次回決算日
該当なし
| 一株当たり利益（EPS） | -2.85 |
| グロス・マージン | 46.97% |
| 純利益率 | -109.95% |
| 有利子負債／自己資本比率 | 27.1% |
BNGO の長期的なパフォーマンスは？
過去の実績と比較を見る企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/05/26 14:39 |
| 終値 | 2026/05/26 00:00 |
| 収益 | 2026/03/31 |
| 年間収益 | 2025/12/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
Bionano Genomics, Inc. 2 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。5
| アナリスト | 機関 |
|---|---|
| Yi Chen | H.C. Wainwright & Co. |
| Jason McCarthy | Maxim Group |
| Kevin DeGeeter | Oppenheimer & Co. Inc. |